Navigation Links
Orexigen(R) Therapeutics Initiates First Clinical Trial of OREX-003 for the Mitigation of Antipsychotic-Associated Weight Gain
Date:10/2/2008

," "assuming," "designed" and similar expressions are intended to identify forward-looking statements. These statements are based on the Company's current beliefs and expectations. These forward-looking statements include statements regarding the enrollment, timing, execution and completion of clinical trials of its product candidates, the potential to obtain regulatory approval for, and effectively treat antipsychotic-associated weight gain with OREX-003, and the scope and duration of protection of issued patents relating to the Company's product candidates. The inclusion of forward-looking statements should not be regarded as a representation by Orexigen that any of its plans will be achieved. Actual results may differ from those set forth in this release due to the risk and uncertainties inherent in the Orexigen business, including, without limitation: the progress and timing of the Company's clinical trials; the potential that earlier clinical trials may not be predictive of future results; the ability for the Company's product candidates to receive regulatory approval on a timely basis or at all; the potential for adverse safety findings relating to the Company's product candidates to delay or prevent regulatory approval or commercialization, or result in product liability claims; the ability of Orexigen and its licensors to obtain, maintain and successfully enforce adequate patent and other intellectual property protection of its product candidates; and other risks described in the Company's filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Orexigen undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of Section 21E of th
'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. OREXIGEN(R) Therapeutics Receives Notice of Allowance for U.S. Patent Covering the Composition of Matter in OREX-003
2. Orexigen(R) Therapeutics Schedules Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2008
3. Orexigen(R) Therapeutics to Present at Upcoming Investor Conferences
4. Orexigen(R) Therapeutics Appoints Dennis Kim, M.D., as Senior Vice President, Head of Obesity and Metabolic Disorders
5. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
6. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
7. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
8. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
9. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
10. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
11. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... Flagship Biosciences LLC, a leading provider of ... medical device industries, has announced a laboratory and office ... consolidated its histology and tissue analysis operations from separate ... north of Denver. The new addresses are: , ... 100, Westminster, CO 80021 , Tissue Image Analysis Lab, ...
(Date:8/27/2014)... 27, 2014 Research and Markets  has ... Ratio Mass Spectrometer Industry Report 2014" report to ... Ratio Mass Spectrometer Industry Report 2014 is a professional ... global isotope ratio mass spectrometer industry. The ... definitions, classifications, applications and industry chain structure. The isotope ...
(Date:8/27/2014)... 27, 2014 Tris Pharma, a specialty pharmaceutical ... announced that it has been selected as an award ... 2014 Awards for Excellence competition in the ... panel of judges from SCORE (Counselors to America,s Small ... be honored at a gala event to be held ...
(Date:8/27/2014)... 27, 2014 BIOEQUA, an innovative line ... use of a handheld spray, has made its EQUA ... , The brand began with an unexpected discovery ... surprised to learn that the application of nanospray technology ... and delivered directly to skin's basal layer. This resulted ...
Breaking Biology Technology:Flagship Biosciences Announces Relocation and Expansion 2Global Stable Isotope Ratio Mass Spectrometer Industry Report 2014 2Tris Pharma Selected as an award winner in the New Jersey Business & Industry Association's 2014 Awards for Excellence 2BIOEQUA'S EQUA ESSENTIAL Product Line Redefines Skin Care & Now Available in America 2
... Inc. (TSX: ONC, NASDAQ: ONCY ) ... combination REOLYSIN(R) and docetaxel clinical trial for patients ... trial is Professor Hardev Pandha of the Royal ... at the Fifth International Meeting on Replicating Oncolytic ...
... marginalized groups including the mentally ill, the disabled ... fare worse than others in the aftermath of ... , Now, a new study by UCLA ... greater terrorism-related fears and make more behavioral changes based ...
... power, and much of that juice comes from fuel cells. ... to find more efficient ways to power them. , In ... metal, is a strong candidate for providing that initial boost ... another popular fuel cell catalyst, platinum, and it,s more abundant. ...
Cached Biology Technology:Oncolytics Biotech(R) Inc. Collaborators Update Combination REOLYSIN(R) and Docetaxel Trial Results at Replicating Oncolytic Virus Meeting 2Oncolytics Biotech(R) Inc. Collaborators Update Combination REOLYSIN(R) and Docetaxel Trial Results at Replicating Oncolytic Virus Meeting 3Disabled and other vulnerable groups more susceptible to terrorism fears 2Brown chemists create more efficient palladium fuel cell catalysts 2
(Date:8/27/2014)... NY (June, 2014) Outstanding basic research, a ... a dedication to patient care have earned the ... University Medical Center (CUMC) and NewYork-Presbyterian Hospital an ... the National Cancer Institute (NCI). The grant renews ... NCI-designated Comprehensive Cancer Centers in New York City ...
(Date:8/27/2014)... associated with outcomes after the repair of peripheral ... mechanism of injury, nerve injured, injury location, defect ... repair materials. However, despite numerous studies of outcomes ... is no agreement regarding the independent predictors of ... the predictors has not been quantified. A study ...
(Date:8/27/2014)... Warwick research finds , Gamblers show the same ... research has shown. , Researchers, led by Dr Elliot ... conducted tests that found that both human gamblers and ... than low-value rewards. , Published in Biology Letters ... the important role that memories of previous biggest wins ...
Breaking Biology News(10 mins):Herbert Irving Comprehensive Cancer Center awarded $18 million grant 2Herbert Irving Comprehensive Cancer Center awarded $18 million grant 3Herbert Irving Comprehensive Cancer Center awarded $18 million grant 4Gamblers are greedy bird-brains, University of Warwick research finds 2
... of Biologists is pleased to announce BIOLOGY OPEN (BiO), ... research across all aspects of the biological sciences including ... journal aims to provide rapid publication for peer reviewed, ... fields. BIOLOGY OPEN will address some big issues ...
... a big effect on their life. Some people are ... which can be detrimental to their health and wellbeing. ... , A new study led by Dr Kathryn ... York has added important experimental evidence showing that animal ...
... fish, one from a Caribbean island and one from the Yucatan ... known in any organism, according to a new UC Davis study. ... Venezuela -- and they are all pretty much the same, said ... with Peter Wainwright, a professor of evolution and ecology at UC ...
Cached Biology News:Announcing BIOLOGY OPEN from the Company of Biologists 2Animals have personalities, too 2'Explosive' evolution in pupfish 2
Request Info...
The Synergy HT utilizes a unique dual-optics design combined with monochromator wavelength selection to provide uncompromised performance in absorbance, fluorescence and luminescence reading modes. ...
... Green I nucleic acid gel stain is ... has bright fluorescence when bound to dsDNA and ... detecting dsDNA in gels using laser scanners or ... stain has also found uses in capillary electrophoresis, ...
Synonym: modified Grace's Insect medium...
Biology Products: